Genetic variation in pro-inflammatory cytokines (interleukin-1β, interleukin-1α and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma

European Cytokine Network

Volumn 16, Issue 4, 2005, Pages 253-260

  Snoussi, Kaouther ^a   Strosberg, A Donny ^b   Bouaouina, Noureddine ^a,c   Ahmed, Slim Ben ^c   Chouchane, Lotfi ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b Department of Infectology ^*  (United States)

^c FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Breast carcinoma; Interleukin 1 ; Interleukin 1 ; Interleukin 6; Polymorphism; Prognosis; Susceptibility

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ADULT; AGED; ALLELE; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; FEMALE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; RISK FACTOR; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CELL SURVIVAL; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 35748938246     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Greene MH. Genetics of breast cancer. Mayo Clin Proc 1997 ; 72 : 54.
2. Dunning AM, Healey CS, Pharoah PD, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1997 ; 8 : 843.
3. Coughlin SS, Piper M. Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999 ; 8 : 1023.
4. Weber BL, Nathanson KL. Low penetrance genes associated increased risk for breast cancer. Eur J Cancer 2000 ; 36 : 1193.
5. Taylor SL, Renshaw BR, Garka KE, et al. Genomics organization of the interleukin-1 locus. Genomics 2002 ; 79 : 726.
6. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996 ; 87 : 2095.
7. Apte RN, Douvdevani A, Zoller M, White RM, Dvorkin T, Shimoni N, Fima E, Hachamj M, Huleilhel M, Benharroch D. Cytokine-induced tumor immunogenecity: endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenecity. Immunol Lett 1993 ; 39 : 45.
8. Castrilli G, Tatone D, Diodoro MG, Rosini S, Piantelli M, Musiani P. Interleukin-1α and interleukin-6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer 1997 ; 75 : 855.
9. Glaccum MB, Stocking KL, Charrier K, Smith JL, Willis CR, Maliszewski C, Livingston DJ, Peschon JJ, Morrisey PJ. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol 1997 ; 159 : 3364.
10. Nozaki S, Sledge GWJR, Nakshatris H. Cancer cell-derived interleukin 1 α contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun 2000 ; 275 : 60.
11. Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, Desai SB. Evidence for transcriptional activation of ERα by IL-1β in breast cancer cells. Int J Oncol 1999 ; 15 : 1251.
12. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R. Expression of interleukin-1β in human breast carcinoma. Cancer 1997 ; 80 : 421.
13. Bailly S, di Giovine FS, Blakemore AIF, Duff GW. Genetic polymorphism of human Interleukin1 α. Eur J Immunol 1993 ; 23 : 1240.
14. Pociot F, Molvig J, Wogensen L, Worsaae H, Neup JA. TaqI polymorphism in the human interleukin1-beta (IL-1βeta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992 ; 22 : 396.
15. Shirodaria S, Smith J, McKay IJ, Kennett CN, Hughes FJ. Polymorphisms in the IL-1α gene are correlated with levels of interleukin-1 alpha protein in gingival crevicular fluid of teeth with severe periodontal disease. J Dent Res 2000 ; 79 : 1864.
16. Dominici R, Cattaneo M, Malferrari G, Archi D, Mariani C, Grimaldi LM. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics 2002 ; 54 : 82.
17. Barber MD, Powell JJ, Lynch SF, Fearson KC, Ross JA. A polymorphism of interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer 2000 ; 83 : 1443.
18. Hutchins D, Steel CM. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 1994 ; 58 : 80.
19. De Jong KP, van Gameren M, Bijzet E, Limburg PC, Sluiter WJ, Slooff JH, de Vries EGE. Recombinant human interleukin-6 induces hepatocyte growth factor production in cancer patients. Scand J Gastroentero 2001 ; 36 : 636.
20. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin-6 induces expression of vascular endothelial growth factor. J Biol Chem 1996 ; 271 : 736.
21. Gemma V, José L, San M, José S, Héctor F. The -597 G/A and -174 G/C Polymorphisms in the Promoter of the IL-6 Are Associated with Hyperandrogenism. J Clin Endocrinol Metab 2002 ; 87 : 1134.
22. Fishman D, Faulds G, Jeffery R, Mohammed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphism in the interleukin-6 (IL-6) gene on IL-6 transcription and serum levels, and association with systemic-onset juvenile chronic arthritis. J Clin Investig 1998 ; 102 : 1369.
23. Bonafe M, Olivieri F, Cavallone L, Giovagnetti S, Marchegiani F, Cardelli M, Pieri C, Marra M, Antonicelli R, Lisa R, Rizzo MR, Paolisso G, Monti D, Franceshi CA. Gender-dependent genetic predisposition to produce high levels of IL-6 is determinal for longevity. Eur J Immunol 2001 ; 31 : 2357.
24. Iacopetta B, Grieu F, Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with aggressive breast cancer phenotype. Br J Cancer 2004 ; 90 : 419.
25. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogent 2004 ; 31 : 167.
26. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Carbal M, Athanasiadis G, Collingan T, Stadtmauer E, Weber B. Interleukin-6 -174 G→C Polymorphism Is Associated with Improved Outcome in High risk Breast Cancer. Cancer Res 2003 ; 63 : 8051.
27. Ben Ahmed S, Aloulou S, Bibi M, Landolsi A, Nouira M, Ben Fatma L, Kallel L, Gharbi O, Khairi H, Kraiem C. Breast cancer detection in Tunisian women : an analysis of a hospital trial involving 729 patients. Sante Publique (Bucur) 2002 ; 14 : 231.
28. Olerup O, Zetterquiest H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in two hours : an alternative to serological DR typing in clinical practice including donor recipient matching in cadaveric transplantation. Tissue Antigens 1992 ; 39 : 225.
29. Tarra L, Mcdowell JA, Symons RP, Øystein F, Gordon WD. A Genetic Association between Juvenile Rheumatoid Arthritis and a Novel Interleukin-1 α Polymorphism. Arthritis Rheum 1995 ; 38 : 221.
30. Kaplan EL, Meir PO. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 ; 53 : 457.
31. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977 ; 35 : 1.
32. Brull DJ, Montgomery J, Sanders S, Dhamrait L, Luong L, Rumley A, Lowe GDO, Humphries S. Interleukin-6 Gene -174G>C and -572 G>C Promoter Polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thomb Vasc 2001 ; 21 : 1458 ; (Biol).
33. Seripa D, Matera MG, Dal Forno G, Gravina C, Masullo C, Daniele A, Binetti G, Bonvicini C, Squitti R, Palermo MT, Davis DG, Antuono P, Wekstein DR, Dobrina A, Gennarelli M, Fazio VM. Genotypes and haplotypes in the IL-1 gene cluster : analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiol Aging 2005 ; 26 : 455.
34. Song X, Vornov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, Bjorkdahl O, Segal S, Dinarello CC, Apte RN. Differential effects of IL-1 alpha and IL-1 beta on tumorigenecity patterns and invasiveness. J Immunol 2003 ; 15 : 6448.
35. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Linfquist R, Barrows J, Kreutzer DL. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 2000 ; 18 : 293.
36. Furuya Y, Ichikura T, Mochizuki H. Interleukin-1 alpha concentration in tumors as a risk factor for liver metastasis in gastric cancer. Surg Today 1999 ; 29 : 288.
37. Singer C, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M, Czerwenka K, Shreiber M, Seifert M, Kubista E. Interleukin-1 system and sex steroid receptor expression in human breast cancer : interleukin-1α protein secretion is correlated with malignant phenotype. Clin Cancer Res 2003 ; 9 : 4877.
38. Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM, Nakshatri H. Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol 2003 ; 163 : 2531.
39. Naume B, Espevik T. Immunoregulatory effects of cytokines on natural killer cells. Scand J Immunol 1994 ; 40 : 128.
40. Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalerta R, Ambrosi A, Franceschi C, Nitti D, Lise M. 174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 2003 ; 9 : 2173.
41. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999 ; 19 : 1427.
42. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001 ; 58 : 1008.
43. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Izuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, Hirose K, Ishihara T, Suzuki T. Relationship between serum levels of interleukin-6, various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 2001 ; 19 : 1457.
44. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, Khayat D, Soubrane C. Endogenous interleukin-6 levels in patients with metastatic malignant melanoma : correlation with tumor burden. Clin Cancer Res 1996 ; 2 : 1405.
45. Berek JS, Chung C, Kaldi K, et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obestet Gynecol 1991 ; 164 : 1038.
46. Wu CW, Wang SR, Caho MF, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996 ; 91 : 1417.
47. Hakan B, Gulcan U, Mustafa S, Mustafa Y, Tomris O, Mehmet A, Hasan A, Ilhan A, Burhan S. Tumour necrosis factor- alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004 ; 27 : 58.
48. Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer : preliminary report. Breast Cancer 2000 ; 7 : 187.
49. Nishimura R, Nagao K, Miyayama H, Mastsuda M, Baba K, Mastsuoka Y, Yamashita H, Fukuda M, Mizumoto T, Hamamoto R. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology 2000 ; 59 : 166.